尼妥珠单抗在食管癌中的应用进展

食管癌是我国常见消化系统恶性肿瘤,对于不可手术切除的局部晚期食管癌,同期放化疗是较为公认的治疗方式,但疗效仍有待提高。尼妥珠单抗作为中国第一个治疗恶性肿瘤的人源化单克隆抗体,已应用于鼻咽癌、神经胶质瘤、胰腺癌等多种恶性肿瘤的治疗,且生存获益显著,不良反应轻微,因此越来越多的学者也关注到其在食管癌治疗中的价值。本文拟对尼妥珠单抗在食管癌中的应用进展进行综述,以期对食管癌的治疗提供新的思路。

Research progress on application of nimotuzumab in esophageal cancer

Esophageal cancer is a common malignant tumor of digestive system in China. Concurrent chemoradiotherapy has become the widely recognized method for the treatment of inoperable locally advanced esophageal carcinoma. Nevertheless, clinical efficacy of concurrent chemoradiotherapy remains to be enhanced. Nimotuzumab, the first human monoclonal antibody to treat malignant tumors in China, has been applied in the treatment of nasopharyngeal carcinoma, glioma, pancreatic cancer and other malignant tumors, which yields significant survival benefits and causes mild adverse events. Hence, more and more scholars are paying attention to its application value in the treatment of esophageal cancer. In this article, research progress on the application of nimotuzumab in esophageal cancer was reviewed, aiming to provide new ideas for the treatment of esophageal cancer.